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Abstract
Amyloidosis is a family of protein misfolding disorders, in which insoluble fibrillar proteins deposit 
extracellularly and cause end organ damage. Depending on the precursor protein, clinical manife-
stations in amyloidosis vary significantly. In systemic amyloidosis, the heart, kidneys, and nerves 
are most commonly affected, resulting in congestive heart failure, arrhythmia, nephrotic syndro-
me, renal failure, and peripheral and autonomic neuropathies. In localized amyloidosis, amyloid 
deposits at the site of production, so only one organ is disrupted. Once amyloidosis is confirmed 
histologically, the precursor subtype must be identified using immunohistochemistry, immunofixa-
tion, electron microscopy, or laser microdissection and mass spectrometry. Treatment should not 
be initiated prior to the identification of the type of amyloidosis. Currently, treatment focuses on 
the suppression of the precursor protein: in AL amyloidosis, chemotherapy or autologous stem cell 
transplants suppress production of immunoglobulin light chains; in AA amyloidosis, anti-micro-
bial and anti-inflammatory agents suppress amyloid A production; and in AF amyloidosis, a liver 
transplantation removes the source of mutant transthyretin protein production. Newer drugs are 
being developed to target amyloidosis at an epigenetic level or stabilize folding intermediates, but 
there are currently in development.
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Introduction
Amyloidosis is a family of protein folding disorders, in which insoluble fibrillar proteins deposit ex-
tracellularly, causing organ damage. By definition, these fibrils have a distinct stain to Congo Red. 
On light microscopy, amyloid deposits have an amorphous, salmon-colored appearance, but give off 
an apple-green birefringence under polarized light [1]. Greater than 28 precursor proteins have been 
described in amyloidosis, the most common being immunoglobulin light chain (AL), transthyretin 
(ATTR), amyloid A (AA), and amyloid β-peptide (Aβ) [2]. The initial step in amyloidogenesis, in 
which a soluble precursor becomes an unstable fragment, is mediated by genetic mutations, proteolytic 
events, environmental factors, or excessive concentration of the precursor protein. The unstable frag-
ments form self-aggregating folding intermediates, which become β-pleated sheets and subsequently 
amyloid fibrils. Serum amyloid P and glycosaminoglycans helps stabilize amyloid fibrils [3]. Amyloid 
fibrils can cause organ damage by disrupting its architecture or direct cytotoxicity [4]. In localized 
amyloidosis, the amyloid deposits at the site of production, whereas deposition occurs remotely in 
systemic amyloidosis. The pattern of organ involvement and clinical manifestations depend largely on 
the precursor protein, although other factors are involved and are not entirely understood. Currently, 
treatment of amyloidosis focuses on suppressing production of the precursor protein, although on-
going clinical trials are aiming to stabilize amyloid fibrils. In this review, I will explore the classification, 
clinical features, diagnosis, and treatment of amyloidosis.
Classification
Amyloidosis falls into two broad categories: systemic and localized (Table 1). The most prevalent and best-
elucidated form of localized amyloidosis is Alzheimer’s disease. In Alzheimer’s disease, Aβ is the major 
component of the amyloid plaques, which cause synaptic injury, widespread neuronal dysfunction, and 
neuronal cell death [5]. In localized AL amyloidosis, plasma cells on mucosal surfaces secrete immunoglo-
bulin light chains that misfold and deposit locally, causing obstruction or a mass effect in the tracheobron-
chial tree, bladder, ureter, or the breast [6-8]. Misfolding of islet amyloid polypeptide or high-dose exoge-
nous insulin can cause amyloid deposition in the pancreas or at the site of administration of insulin [9].
The most common systemic amyloidosis in the developed countries is AL amyloidosis, affecting 6-10 
persons/million/year in the United States [10]. AL amyloidosis is a plasma cell dyscrasia in which 
misfolded immunoglobulin light chains can disrupt the function in most organs, except the brain and 
vitreous fluid. Specific amino acids in certain loci of the variable domain destabilize the light chain and 
promote amyloidogenesis [11].
In AA amyloidosis, uncontrolled inflammation or infections lead to the overproduction of amyloid A 
protein, which is amyloidogenic. Interleukin-1 (IL-1), IL-6 and tumor necrosis factor-α (TNF-α) are 
the primary inflammatory cytokines that stimulate the release of serum amyloid A. The cause of the 
underlying inflammation varies largely on geography and access to effective therapies. In developed 
countries, rheumatologic disorders, primarily rheumatoid arthritis, juvenile rheumatoid arthritis, and 
ankylosing spondylitis, cause up to 60-75% of AA amyloidosis [12-14]. Other inflammatory proces-
ses, such as inflammatory bowel disease and periodic fever syndromes, can cause up from 2-14% of 
AA amyloidosis, although rates may be higher in countries bordering the Mediterranean Sea [12-15]. 
Tuberculosis, osteomyelitis, bronchiectasis, recurrent bacteremia from intravenous drug use and other 
infectious causes are more prominent in the developing world or amongst recent immigrants [15]. 
With improvement of anti-microbial and immunosuppressive therapy, the underlying cause for in-
flammation is not always obvious despite a thorough work up. Patients without an identifiable cause of 
inflammation have more cardiac involvement and may have a worse prognosis [16,17].
Type Precursor protein Organ involvement Treatment options
Localized Localized AL Immunoglobulin light chain Tracheobronchial, bladder, 
ureter, breast
Resection, laser excision, 
conformal radiotherapy
Alzheimer’s 
disease
Aβ protein precursor Brain Acetylcholine esterase 
inhibitor, NMDA receptor 
antagonist
Systemic AL amyloidosis Immunoglobulin light chain Heart, kidney, autonomic and 
peripheral nervous system, GI 
tract, liver, spleen, pulmonary, 
endocrine, soft tissue
Chemotherapy, 
autologous stem cell 
transplantation
AA amyloidosis Serum amyloid A Kidney, GI tract, spleen, 
andocrine, rarely heart and 
autonomic nervous system
Suppressing underling 
inflammation
Familiar 
amyloidosis
Mutant transthyretin Heart, autonomic and 
peripheral nervous system, 
soft tissue
Liver transplantation, 
investigational drugs 
(diflunasil, tifamidis, 
doxycycline, siRNA, ASO)
Age-realted 
amyloidosis
Wild-type transthyretin Heart, soft tissue Supportive care
Less common 
familial 
amyloidosis
Apolipoprotein A1, apolipoprotein 
AII, fibrinogen Aα chain, lysozime, 
gelsolin, cystatin C
Varies based on precursor 
protein/mutation
Supportive care
Table I. Types of localized and systemic amyloidoses
ASO = Anti-sense deoxynucleotides; siRNA = small interfering RNA
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Amyloidosis involving the transthyretin (TTR) can occur as variant (ATTR) or wild-type. Transthyre-
tin protein is a transport protein for thyroid hormone and retinoic acid, although gene-expression 
profiling suggest an additional role in altering chaperone molecules intracellularly [18]. ATTR, a form 
of familial amyloidosis, is a family of inherited amyloidosis due to single nucleotide polymorphisms in 
the transthyretin protein. While >100 have been identified, approximately 80 are pathologic [19]. The 
most common mutations include isoleucine-122, methionine-30, and alanine-60 and symptom onset 
and organ involvement can vary significantly, based on the mutation.
Wild-type TTR can aggregate and form amyloidosis in the age-related or senile-systemic amyloidosis 
(SSA). SSA, a disease of aging, predominantly affects men (50:1 male:female expression) and deposits 
exclusively the heart [20]. Clinically significant congestive heart failure from cardiac amyloidosis in 
SSA can occur in 5.5% to 16% of elderly aged at least 80 years [21,22]. However, autopsy series have 
detected scattered, clinically irrelevant amyloid deposition in 10-25% over the age of 80. After liver 
transplantation, case reports have shown accelerated deposition of wild type TTR in the native heart, 
even at younger ages [23]. The cause of aggregation of wild type TTR has not been elucidated. Variant 
and wild type TTR can be differentiated only with genotyping.
Other, less frequent forms of amyloidosis have been described. Dialysis-related amyloidosis, due to 
aggregation of β-2 microglobulin, deposits in the bone or peri-articular tissue. It is less common with 
modern hemodialysis techniques, in which newer high flux dialysis membranes effectively filter β-2 
microglobulin; it can still occur with peritoneal dialysis [24]. Several other rare familial amyloidoses 
have been described, with mutations genes coding for apolipoproteinA1, apolipoproteinA2, fibrino-
gen, gelsolin, lysozyme, and cystatin, each with different organ involvement and age of onset based on 
the precursor type and locus of mutation.
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Clinical features
In amyloidosis, multiple organs can be affected and a thorough physical and laboratory examination is 
necessary to determine the extent of involvement. A systematic assessment may provide clues about the 
precursor protein and help anticipate and minimized toxicities of treatment (Table II).
Organ-specific clinical features
A cardiac event is the most common cause of death in amyloidosis. Patients with cardiac involvement 
have rapid and progressive congestive heart failure or arrhythmias. Less frequently, in the setting of 
amyloid deposition in the small vessels of the heart, patients can have anginal symptoms, but a normal 
coronary angiogram [25]. On physical examination, patients have signs of right-sided heart failure 
with bilateral leg edema, elevated jugular venous pressures, and hepatomegaly. Electrocardiography 
(ECG) can show low-voltage on limb leads with a pseudo-infarct pattern, q waves in the pattern of 
a coronary artery. This occurs more frequently in AL amyloidosis than SSA [26]. Echocardiography 
reveals concentric left, and sometimes right, ventricular hypertrophy, an enlarged interventricular sep-
tum, and a normal or slightly reduced left ventricular ejection fraction [1]. The interventricular septum 
is thicker in SSA than AL amyloidosis (17.8 mm vs. 14.3 mm, p=0.002) [20]. A diminished mitral A 
wave, the result of increased left-sided filing pressures and atrial infiltration by amyloid, increases the 
risk for atrial thrombosis and systemic embolic disease; systemic anti-coagulation may be warranted 
Organ involved Symptoms Signs Other
Heart Congestive heart failure, 
angina, arrhythmia
Bilateral leg edema, elevated 
JVP, hepatomegaly
ECG: low voltage limb leads, pseudo-
infarct pattern. Echocardiogram: 
concentric LVH, increased 
interventricular septal thickness
Kidney Leg swelling, abdominal 
distension
Leg edema, anasarca Nephritic syndrome
Peripheral 
neuropathy
Numbness pain Decreased deep tendon 
reflexes, loss of vibration 
sense
Autonomic 
neuropathy
Nausea, vomiting, bloating 
early satiety, colic, dry eye/
mouth, erectile dysfunction
Orthostatic hypotension
Gastrointestinal 
tract
Malabsorption, hemorrhage, 
pseudo-obstruction
Cachexia Positive stool guaics
Liver/spleen Hepatic/splenic rupture Hepato-/splenomegaly Elevated alkaline phosphatase, Howell-
Jolly bodies
Pulmonary/
tracheo-bronchial
Hoarseness, recurrent 
pneumonia, exertional 
dyspnea
Airway obstruction, pleural 
effusions
Bronchoscopy: nodular/irregular airway. 
Pulmonary Function Tests: distal/
proximal obstruction, decreased DLCO.
CT: interlobular septal thickening in 
basilar and peripheral destruction
Soft tissue Impaired speaking or eating Macroglossia, submandibular 
gland enlargement, 
peri orbital ecchymoses
Coagulopathy Thrombosis/bleeding Low factor X levels
Table II. Clinical Features of amyloidosis
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even in the absence of atrial fibrillation [27]. Newer techniques, such as tissue Doppler imaging and 
strain Doppler imaging, have improved detection of cardiac amyloidosis at an early stage [28]. Cardiac 
magnetic resonance imaging (MRI) helps differentiate amyloidosis from other forms of hypertrophic 
cardiomyopathy, with the former showing global late enhancement of the subendocardium [29]. In 
ATTR, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy can identify 
early cardiac involvement despite normal ECG or echocardiography, which is particularly important 
in certain phenotypes in which only the heart is involved. Furthermore, only one-third of patients with 
AL amyloidosis with cardiac involvement have positive scans, so 99mTc-DPD scintigraphy can some-
times be used to differentiate ATTR from AL amyloidosis [30]. 99mTc-DPD scintigraphy has a role in 
diagnosis and prognosis of SSA [31].
Serum cardiac biomarkers play a critical role in determining prognosis, especially in AL amyloidosis. 
In AL amyloidosis, a prognostic model of overall survival using troponin T (TnT), and N-terminal 
prohormone of brain natriuretic peptide (NT-proBNP) was proposed and showed the median survival 
in stage I was 26.4 months, compared to 3.5 months in stage III [32]. An updated prognostic model, 
devised in the current era of novel chemotherapeutic agents and autologous stem cell transplantation, 
includes serum free light chain (FLC) measurements and demonstrated a wide range of median survi-
val, ranging from 94.1 months in stage I to 5.8 months in stage IV [33]. Serum cardiac biomarkers can 
also be elevated in SSA and ATTR, but their prognostic role has not been elucidated [26,34].
Amyloidosis, especially AL and AA, can involve the kidneys. Most commonly, amyloid fibrils depo-
sit in the glomeruli, resulting progressive nephrotic syndrome and renal failure, resulting in dialysis-
dependence [3]. In AL amyloidosis, the predominant protein excreted is albumin and the amount can 
exceed 30 grams daily [3]. The resultant hypoalbuminemia can impede effective diuresis. Amyloid de-
position in the tubulointerstitium can cause progressive renal failure in the absence of proteinuria, but 
this process is more indolent. Rare manifestations of amyloid deposition include nephrogenic diabetes 
insipidus, due to deposition in the peri-collecting duct tissue, and Fanconi’s syndrome, due to proximal 
tubule injury from light chains [35,36].
Amyloid deposition in the nerves can cause both peripheral and autonomic neuropathy. Peripheral 
neuropathy can present in stocking-glove distribution with loss of vibration or sensation, absence of 
deep tendon reflexes, and painful or burning dyesthesias. Symptoms of autonomic neuropathy inclu-
de orthostatic hypotension (74%), gastrointestinal (GI) symptoms with nausea, vomiting, bloating, 
early satiety, and colic (71%), secretomotor symptoms with dry eyes or dry mouth (54%), and erectile 
dysfunction (67%) [37]. Autonomic neuropathy rarely occurs in the absence of peripheral neuropathy.
Gastrointestinal tract and the reticuloendothelial system can be involved too. Symptoms of GI in-
volvement include malabsorption, pseudo-obstruction, weight loss, and hemorrhaging [1,38]. The 
presence of GI amyloidosis does not necessarily indicate systemic disease as approximately 20% of 
cases are due to localized amyloidosis [39]. Amyloid fibrils deposit in the liver, resulting in hepatome-
galy, elevated alkaline phosphatase, and rarely spontaneous hepatic rupture [40,41]. Likewise, splenic 
dysfunction, illustrated by the presence of Howell-Jolly bodies, and spontaneous rupture have been 
described [42,43].
Pulmonary and airway amyloidosis, which can occur in both systemic and localized disease, typically 
presents with dyspnea, hemoptysis, exertional dyspnea, or hoarseness. Amyloid can deposit in four 
different areas of the lung: interstitial, nodular, pleural, and tracheobronchial [6]. Most commonly, 
submucosal deposition in the tracheobronchial airway results in airway obstruction, recurrent pneu-
monia, hoarseness, and segmental collapse [8,44]. Imaging and bronchoscopy show nodular and irre-
gular narrowing of the airway. Pulmonary function tests vary depending on location of the amyloid, 
whether involving the tracheobronchial tree proximally or distally. Second, diffuse interstitial disease 
presents with functional deterioration, although this decline is more commonly due to cardiac amyloi-
dosis [6]. Chest roentgenography shows a reticuloendothelial pattern; a computed tomography of the 
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thorax shows interlobular septal thickening in basilar and peripheral distribution [44]. Pulmonary 
function test reveal impaired gas exchange. Third, amyloid can deposit in the pleura causing recurrent 
unilateral pleural effusions; bilateral pleural effusions more commonly signify severe cardiac amyloi-
dosis [6]. Last, nodular amyloidosis presents as an amyloidoma, a non-cavitary pulmonary nodule, and 
is rare.
Soft tissue and endocrine glands can be involved. Adrenal and thyroid infiltration result in adrenal in-
sufficiency and hypothyroidism, respectively. Deposition in the tongue can cause macroglossia, an en-
larged tongue with tooth impressions laterally and rigidness or crunchiness to palpation. Macroglossia 
can be functionally debilitating with impairing mastication, swallowing, and speech. Submandibular 
enlargement can be prominent on physical exam. Spontaneous peri-orbital ecchymosis or purpura 
from vascular deposition can be a subtle marker of amyloidosis. Nail dystrophy and hair loss can occur 
too. Finally, factor X deficiency significantly impairs hemostasis and is pathognomonic for AL amyloi-
dosis.
AL amyloidosis
AL amyloidosis has the widest range of organ involvement and most commonly affects the kidneys 
(46%) and heart (30%) [1]. Cardiac involvement is associated with shorter survival and increased to-
xicity to therapy in AL amyloidosis, with 40% dying from heart failure or arrhythmias [45]. In AL 
amyloidosis, troponin I (TnI), troponin T (TnT), N-terminal prohormone of brain natriuretic peptide 
(NT-proBNP), and serum free light chains (FLC) are all predictors of survival and should be part of 
routine work up [32]. Factor X deficiency and macroglossia are almost pathognomonic for AL amyloi-
dosis.
AA amyloidosis
AA amyloidosis most commonly affects the kidneys, but can also involve the GI tract, adrenals and the 
reticuloendothelial system. Autonomic and cardiac involvement is rare and occurs only late in disease 
course [13]. Nephrotic syndrome slowly improves with suppression of inflammation, but can deterio-
rate rapidly when the inflammation returns. Risk factors for poor prognosis included age, hypoalbumi-
nemia, end stage renal failure at baseline, and mean arterial pressure [12,13].
ATTR amyloidosis
The individual mutation in TTR predicts the phenotype in familial amyloidosis, including age of onset, 
clinical course, and prognosis. Variant TTR follows an autosomal dominant pattern and commonly 
affects the peripheral nervous system with or without heart involvement. Vitreous involvement occurs 
almost only in variant TTR. The most prevalent mutation is the valine-to-methionine substitution at 
position 30 (Met-30 or V30M). Arising predominantly in Japan, Portugal, or Sweden, Met-30 follows 
two different patterns. In mutations arising in patients with Japanese or Portuguese ancestry, Met-30 
has high penetrance, early age of onset (twenties to early forties), and rapid progression of autono-
mic- and polyneuropathy. In patients with Swedish ancestry, age of onset is the middle fifties with low 
penetrance and slow progression [46]. Cardiac disease commonly presents with arrhythmias, rather 
than heart failure. The threonine-to-alanine substitution at position (Ala-60 or T60A), occurring pre-
dominantly in patients with Irish and British ancestry, results in polyneuropathy and cardiac invol-
vement. Cardiac involvement is nearly universal, some series reporting 100% involvement [21]. The 
most common variant TTR affecting only the heart is the valine-to-isoleucine substitution at position 
122 (Ile-122 or V1221). Ile-122 is seen in the Caribbean Islands and among African-Americans in the 
United States [47]. Genotypically, it is present in 4% in this population, but penetrance is incomplete. 
Compared to aged-, gender-, and ethnically matched population, Ile-122 is associated with higher fre-
quency of congestive heart failure (38% vs. 15%, relative risk 2.62, p=0.084) and trend towards lower 
mortality (relative risk 1.46, p=0.08) [48].
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Diagnosis
Even with high clinical suspicion, a tissue biopsy is necessary for diagnosis of amyloidosis. On Congo red 
stain, amyloid appears red on light microscopy, but apple-green under polarized light (Figure 1) [1]. While 
Congo red stain is the gold standard, this is typically performed only when the pathologist has a high level 
of suspicion for amyloidosis. Other more commonly performed histological techniques can be suggestive 
of amyloidosis. On hematoxylin and eosin stain, amyloid appears as a salmon-colored pink, amorphous 
extracellular substance. Thioflavin T, which is less specific than Congo red, stains amyloid yellow on light 
microscopy and red with fluorescence [49]. On electron microscopy, amyloid fibrils are non-branching, 
randomly arranged, and have a 7 to 12 nm diameter and can be diagnostic of amyloidosis [2].
While the affected organ has the highest sensitivity, a biopsy of the abdominal fat pad is safer, less 
invasive, and commonly the first diagnostic step. A limited amount of abdominal fat is necessary for 
diagnosis, so a fine needle aspirate is sufficient. The fat pad aspiration has 80-90% sensitivity for AL 
amyloidosis, but only 65-75% for AA amyloidosis [50]. In localized amyloidosis, amyloid fibrils deposit 
locally and the fat pad aspirate is negative. If the fat pad aspirate is negative and suspicion for amyloido-
sis is high, then the involved organ should be biopsied. The sensitivity of a biopsy of an involved heart is 
100%, liver is 97%, and kidney is 94% [2]. In familial amyloid polyneuropathy, a sural nerve biopsy has 
only 33% sensitivity, so a rectal biopsies can be attempted if the nerve biopsy is normal [51].
Once the diagnosis of amyloidosis is confirmed, the precursor protein must be identified prior to star-
ting treatment since treatment will vary based on the type of amyloidosis. For instance, amyloid infil-
tration of the heart can occur in AL amyloidosis, SSA, or familial amyloidosis due mutant TTR. While 
99mTc-DPD scintigraphy, interventricular wall thickness, and cardiac biomarkers can be suggestive of 
one type of amyloidosis, these tests are not diagnostic. Without identification of the type of amyloido-
sis, patients can be treated for the inappropriate type of amyloidosis. For example, an elderly patient 
with SSA and an MGUS, both diseases with an increased prevalence in the elderly, are sometimes inap-
propriately treated with a systemic chemotherapy, even though both diseases should only be observed. 
To prevent any incorrect therapy, the precursor protein should be identified using any available invol-
ved tissue, including the fat pad.
It is important to note that the presence of a hypertrophic cardiomyopathy in systemic amyloidosis 
is not necessarily diagnostic of cardiac amyloidosis. The differential for left ventricular hypertrophy 
Figure 1. Amyloid on Congo red: red on light microscopy (A) and apple-green under polarized light (B)
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includes hypertensive cardiomyopathy, hypertrophic obstructive cardiomyopathy, and other rare in-
filtrate cardiomyopathies. Hypertensive heart disease can be differentiated from amyloid cardiomyo-
pathy by increased or normal voltage on ECG in the former. Echocardiography can also differentiate 
amyloidosis from other hypertrophic cardiomyopathy by diffusely increased echogeneitic and in-
creased interatrial septal thickness. An endomyocardial biopsy is the gold standard to differentiate 
hypertrophic cardiomyopathies, but should only be performed if it will change clinical decision ma-
king.
The first step in typing the amyloid is immunofluorescence and immunohistochemistry using antibo-
dies against immunoglobulin light chains, TTR, and amyloid A. Due to the nature of amyloid, even 
the commercially available antibodies can be inaccurate. For instance, the variability in light chains or 
structural changes in variant TTR may impair antibody interaction with the epitope, yielding a false 
negative. Second, charge interactions between amyloid and the reagent can cause false positives, espe-
cially in AA [2]. To reduce background and non-specific staining, immunofluorescence is preferred 
over immunohistochemistry, but requires fresh or paraffin-embedded tissue.
If the subtype is still not identified, immunogold electron microscopy or laser microdissection and 
mass spectrometry should be performed. In immunogold electron microscopy, gold-labeled anti-
bodies directed again common subtypes stain tissue sections. This technique allows visual confir-
mation that the gold-labeled antibodies bind the amyloid fibril, allowing exclusion of non-specific 
binding to the background. However, it has the aforementioned limitations related to the antibodies. 
Laser microdissection and mass spectrometry is becoming increasingly important in typing amyloi-
dosis. Amyloid deposits are identified with Congo red, dissected under microscopy, digested with 
tryptic peptides, then analyzed by liquid chromatography mass spectroscopy [52]. The initial series 
found 98-100% sensitivity and specificity to detect the most common amyloidosis types. Subsequent 
series have described accurate detection of rare forms of amyloidosis [53]. Thus, mass spectrometry 
is becoming the gold standard due to its high sensitivity and specificity, as well as its ability to iden-
tify rare forms of amyloidosis. Current barriers to widespread use including the technical expertise 
and cost.
If TTR is detected, differentiating variant from wild-type form is necessary and is achieved in two steps: 
isoelectric focusing and genotyping. Isoelectric focusing, a process of separating variant from wild type 
TTR using gel electrophoresis, has 96% sensitivity and 100% specificity [54]. In SSA, only one band is 
present; in ATTR, two bands are present: variant and wild type. If variant TTR is demonstrated, genot-
yping of the TTR gene is necessary to determine the mutation.
Scintigraphy with radioisotope labeled serum amyloid P component (SAP) can visualize amyloid depo-
sits in most organs, but it has limited benefit. Serum amyloid P, which along with glycosaminoglycans 
helps stabilize amyloid fibrils, is universally present in all amyloidosis, irrespective of the subtype. The 
burden of amyloid deposits can be reproducibly quantified with SAP, although clinically relevant organ 
involvement can be easily determined with physical exam and laboratory findings. While detection of 
heart involvement certainly alters treatment options, cardiac MRI is more sensitive than SAP, which 
cannot reliably image the heart [2].
Treatment
Current therapies suppress or stabilize of the precursor protein formation and interfere with fibrillo-
genesis. In AL amyloidosis, chemotherapy with or without autologous stem cell transplantation can 
be curative. In AA, treatment focuses on stopping the underlying cause of inflammation. In ATTR 
amyloidosis, orthotopic liver transplantation is curative. For SSA and other less common amyloidoses, 
treatment is typically supportive.
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AL amyloidosis
Chemotherapy strategies in AL amyloidosis are usually extrapolated from management of multiple 
myeloma, but the toxicities are typically more significant in amyloidosis. Treatment strategies remain 
controversial, with some advocating for high dose chemotherapy with autologous stem cell transplan-
tation, while others recommend standard dose chemotherapy only. One randomized, phase III clinical 
trial compared standard dose melphalan with dexamethasone and high-dose melphalan with autolo-
gous stem cell transplantation (HDM/SCT) [55]. Although this was designed as a non-inferiority trial, 
the standard dose melphalan arm had longer survival (56.9 vs. 22.2 months, p=0.04). This should be 
interpreted with caution, since the HDM/SCT transplant arm had 26% treatment-related mortality 
and an addition 20% died prior to receiving the stem cell infusion. With appropriate patient selection, 
institutional experience, and improved anti-microbials, the treatment-related mortality can be reduced 
to 1-5% [56,57]. While upfront morbidity and mortality are undeniable, long term remission can be 
achieved; median OS in all patients treated HDM/SCT was 6.3 years, up to 13.2 years in patients who 
had a hematologic complete response [56]. Given the potential for cure, patients with AL amyloidosis 
should be evaluated by an experienced center for HDM/SCT.
AL amyloidosis is currently undergoing a treatment renaissance with the advent of novel agents. Che-
motherapy typically consists of two or three drugs, almost universally including corticosteroids. While 
these new drugs are efficacious, toxicities are more severe in amyloidosis and initial doses are typically 
lower than in other hematologic malignances. Even corticosteroids can result in significant volume re-
tention in patients with cardiac or renal involvement. Dexamethasone and the alkylating agent melpha-
lan have formed the core of treatment until recently, resulting in response rates up to 67% and median 
OS to 5.1 years [58,59]. More recently, the combination of the proteosome inhibitor bortezomib and 
dexamethasone has become widely used, due to the tolerability and rapid onset of action. A recent 
Phase 1/2 trial showed that time to first and best response was 0.7 and 1.2 months, respectively, with 
a twice-weekly regimen [60]. Significant toxicity, dose reduction, and discontinuation of bortezomib 
can be reduced with once weekly dosing. If a rapid response is necessary due to rapidly progressing in-
volvement of a critical organ, one strategy is to initiate twice weekly dosing and reduce to once weekly 
when a satisfactory response is achieved.
Immunomodulators have had variable success in AL amyloidosis. Thalidomide is rarely used and is 
poorly tolerated due to bradycardia, dyspnea, edema, and fatigue. Two prospective studies showed 
Grade 3 or 4 toxicities in up to 65% of patients and up to half withdrew due to toxicity [61,62]. The 
second-generation immunomodulator lenalidomide is better tolerated, but patients with chronic re-
nal insufficiency or cardiac involvement particularly suffer grade 3 to 4 toxicity in 50-75% of patients 
[63,64]. With a reduced dose, response rates are as high as 47% and median progression free survival 
is 4.2 years. One prospective study evaluated the third generation pomalidomide and results are pro-
mising. In a pre-treated cohort, almost 50% had a hematologic response, only 9% withdrew from the 
study due to toxicity, and the one-year progression free survival was 59% [65].
Triplet chemotherapy is also showing promise in AL amyloidosis. Cyclophosphamide, bortezomib, 
and dexamethasone had a 94% hematologic response rate and improved functional capacity in some 
patients, allowing them to undergo HDM/SCT. Despite multi-organ disease and 59% (n=10) having 
advanced cardiac amyloidosis, the regimen was remarkable well tolerated [66]. Caution should be used 
interpreting this data since this was a small, retrospective series with inherent selection bias and varia-
ble entry criteria. The combination of bortezomib, melphalan, and dexamethasone has been studied 
in prospectively, although the results are available in abstract form only [67]. Again, the hematolo-
gic response rate was 94%, but 75% had grade 3/4 thrombocytopenia and required dose-adjustments. 
Long-term survival data are incomplete, so triplet chemotherapy cannot yet be considered a standard 
of care. Nonetheless, incredible progress has been made over the last decade in both standard dose 
chemotherapy and autologous stem cell transplantation.
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AA amyloidosis
Serum amyloid A production is driven by inflammation, so treatment of AA amyloidosis should focus 
on controlling the underlying disease. The earliest successful example was treatment of familial Medi-
terranean fever (FMF) with colchicine to prevent AA amyloidosis. Although the pathophysiology of 
FMF is not clear, colchicine can prevent attacks [68]. Compared to non-compliance, the adherence to 
prophylactic colchicine reduced the incidence of AA amyloidosis from 30% (16/54) to 0.4% (4/960) 
[69]. Suppression of inflammation from many underlying diseases has caused regression of AA amyloi-
dosis in multiple case reports and small series. In rheumatoid arthritis, initiation of biological therapies 
can reduce in serum amyloid A and proteinuria, and improve kidney function [70]. Resection of loca-
lized Castleman’s disease has resulted in regression of amyloid deposition [71,72].
In AA amyloidosis, an investigational drug targets fibril formation. Eprodisate is a negatively char-
ged, sulfonated molecule that interferes with the interaction between glycosaminoglycans and amyloi-
dogenic proteins, inhibiting formation of amyloid fibrils. In a double-blinded, randomized trial, the 
eprodisate had a trend towards preventing worsening renal disease (p=0.06) and decreasing the rate 
of decline in creatinine clearance, but did not prevent progression to end-stage renal disease or death 
[73]. The Food and Drug Administration (FDA) did not approve this medication, thus a new clinical 
trial (NCT01215747) is accruing patients.
ATTR amyloidosis
Since the majority of TTR protein is produced in the liver, orthotopic liver transplantation (OLT) has 
become the standard of care for some familial amyloidoses. An OLT replaces production of variant 
TTR with non-amyloidogenic wild type TTR, theoretically preventing the progression of familial 
amyloidosis. Nearly 2,000 OLT have been performed worldwide, primarily in patients with V30M [21]. 
One single-center study showed survival advantage with OLT compared to supportive care at 10 years 
(83% and 62%) and 15 years (60% vs. 19%, p<0.001) [74]. Despite an OLT, progressive amyloid car-
diomyopathy and neuropathy can occur in a subset of transplanted patients [21,75]. The new fibrils 
depositing in the heart are wild type TTR, with previously deposited variant TTR acting as a catalyst 
for fibrillogenesis.
While OLT can be curative, it requires identification of appropriate donors, availability of a liver, major 
surgery, and long-term immunosuppression. Therefore, other therapies are necessary. The rate-limiting 
step in TTR fibrillogenesis is TTR dissociation and monomer misfolding. Diflunisal, an FDA-approved 
non-steroidal anti-inflammatory drug, binds the thyroxine binding site on TTR, stabilizing the tetra-
mer, raising the activation energy for dissociation, and inhibiting fibrillogenesis [76]. Pharmacokine-
tics suggests that adequate serum concentrations can be reached to stabilize TTR [76]. A single-arm, 
open label Phase I/II study showed that diflunisal can be given safely in cardiac amyloidosis [77]. A 
randomized Phase 3 trial (NCT00294671) to determine the effect of diflunisal on progression of neu-
ropathies has finished accrual and results should be available soon. A second small molecule tafamidis 
also stabilizes the TTR tetramer through interaction with the thyroxine-binding site. A randomized, 
placebo-controlled, double-blinded study did not show a statistically significant improvement in neu-
ropathic symptoms by intention-to-treat analysis. Given the higher-than-anticipated liver transplan-
tation dropout rate, efficacy evaluable analysis was performed and showed that tafamidis improved 
neuropathic scores and a significant delay in neurologic progression [78]. Importantly, it stabilizes 
not only the most common forms variant TTR, but also wild type TTR [79]. Unlike the European 
Medicines Agency that approved the drug, the FDA requested additional studies and a second trial 
(NCT01435655) is currently recruiting patients. Doxycycline is another small molecule that is un-
dergoing investigation in amyloidosis. In a mouse-model for TTR and AL amyloidosis, doxycycline 
inhibited amyloid formation [80,81]. A phase II, open-label study of doxycycline with tauroursodeoxy-
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cholic acid showed an acceptable safety profile and stable disease for one year in a 20 patient cohort 
[82]. Additional phase II trials are accruing patients. Last, newer techniques are targeting expression 
of TTR on a genetic level. In a transgenic mouse model, antisense oligonucleotides can suppress TTR 
levels by 80% [83]. Industry sponsored Phase II/III trials for small interfering RNA (NCT01617967) 
and antisense oligodeoxynucleotides (NCT01737398) are or soon will recruit patients [21].
Localized AL amyloidosis
Treatment of localized amyloidosis consists of local therapy to resect amyloid deposits or ablate the 
plasma cells. Of the localized AL amyloidoses, tracheobronchial airway has the strongest data. Laser 
excision is currently the standard of care, since it not only removes the involved tissue, but may also kill 
the plasma cells producing the light chains. Therapy needs to be repeated frequently, requiring 2 to 4.7 
treatments annually, depending on the location in the airway [6]. Eventually, scar tissue forms in the 
airway and patients develop untreatable, progressive respiratory compromise and survival a median of 
9 years after diagnosis [8]. Conformal radiotherapy has shown benefit in a retrospective review in pro-
gressive airway amyloidosis, with prevention of additional deposition in 8/10 patients and improved 
functional capacity without late morbidity [84]. In cases of diffuse lung involvement from aggressive, 
localized amyloidosis, corticosteroids were not effective and systemic chemotherapy can rarely be con-
sidered [6]. Other localized amyloidoses are also treated with local therapy. Bladder amyloidosis can be 
treated with transurethral resection, although some cases require a cystectomy and urinary diversion 
[85]. Breast amyloidosis, which presents with calcification on mammography, requires local excision 
to exclude malignancy, even with recurrence. In a small series of 7 patients, one had an invasive ductal 
adenocarcinoma in addition to amyloidosis [7].
Supportive Care
Since amyloidosis is frequently not curable, supportive care is necessary to prolong life and impro-
ve its quality. Cardiac amyloidosis causes significant morbidity, so management of volume status and 
dysrhythmias is critical and difficult. The combination of loop diuretics and spironolactone is effective 
in managing the volume status, although low dose metolazone may be necessary up to 3 times weekly. 
Volume overload and subsequent poor cardiac output can result in renal failure, making diuresis har-
der. Conversely, overdiuresis, especially with metolazone, can rapidly cause orthostatic hypotension 
and renal failure. Cardiac amyloidosis causes diastolic dysfunction, so a compensatory sinus tachycar-
dia should not be blunted [21]. While low doses of β-blocker can be beneficial by increasing the time in 
diastole and improving filling and cardiac output, calcium channel blockers and digoxin are an absolute 
contra-indication. Both can bind amyloid fibrils, the former reducing stroke volume and exacerbating 
congestive heart failure and the latter increasing the risk of digoxin toxicity. Low dose angiotensin-con-
verting enzyme inhibitors and angiotensin receptor blockers can cause severe hypotension, especially 
in patients with autonomic nervous system involvement [86]. Atrial fibrillation are best managed with 
low dose β-blockade (up to 100 mg of metoprolol daily) and amiodarone [21]. Orthotropic heart tran-
splantation (OHT) has an established role in ATTR and has emerging data in AL amyloidosis [21,87]. 
One retrospective series showed that in patients with severe cardiac involvement that prohibited SCT, 
OHT followed by HDM/SCT is feasible and may lead to a survival benefit [87].
Irrespective of the precursor protein, untreated renal amyloidosis will eventually progress to end 
stage renal disease (ESRD). While suppression of the precursor protein can improve the proteinuria 
and stabilize renal function, patients may nonetheless progress to ESRD [70-72,88]. In amyloidosis, 
renal transplantation can be safely performed after successfully suppressing the precursor protein. In 
AL amyloidosis, one small series showed that there was no graft failure due to recurrent amyloidosis 
at a median follow up of 5 years [89]. In AA amyloidosis, recurrent amyloidosis nephropathy recur-
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red in 14% of patients, especially in those continued underlying inflammation [90]. Patients with 
ESRD from amyloidosis can be evaluated for kidney transplant, especially if the precursor protein is 
controlled.
Treatment of peripheral and autonomic neuropathies in amyloidosis is similar to management of other 
neuropathies. Midodrine is effective in increasing standing blood pressure and should be given three 
times in the morning, noon, and late afternoon. This can be used in symptomatic patients or in antici-
pation of hypotension from diuresis. Fludrocortisone is a second line therapy, but can aggravate fluid 
retention. Early satiety can be improved with small, frequent meals. Reglan can be helpful with gastro-
paresis. Loperamide, atropine/diphenoxylate, octreotide, and tincture of opium can control diarrhea. 
Gabapentin, pregabalin, or opiate analgesia can be used to manage painful dyesthesias.
Conclusion
In summary, amyloidosis is a family of protein misfolding disorders, defined by extracellular deposi-
tion of a fibrillar protein that stains with Congo red. Due to its rarity and non-specific symptoms, dia-
gnosis is commonly delayed and organ dysfunction can be significant at diagnosis. Advancements in 
histology and proteomics have significantly improved the ability to identify the precursor protein, but 
clinicians and pathologist must consider amyloidosis on their differential for the appropriate tests to be 
ordered. Treatment of systemic amyloidosis and suppression of the precursor protein has changed dra-
matically over the last decade. Newer anti-plasma cell, antimicrobial, and anti-inflammatory agents 
have improved outcomes in AL and AA amyloidosis, but treatment of familial amyloidosis is under-
going the most exciting changes: small molecules that stabilize TTR or affect TTR production at an 
epigenetic level.
Questions for further research
Currently, treatment of amyloidosis focuses on suppression of the precursor proteins, although 
some clinical trials are now attempting to stabilize the folding intermediates to reduce deposition 
of amyloidosis. Future studies in AL amyloidosis should compare the long-term survival in patients 
treated with novel agents and autologous stem cell transplantation. A second major research fo-
cus should attempt to resorb the deposited amyloid fibrils, in hopes of reversing end-organ da-
mage. This could ultimately decrease the morbidity of treatment and improve the quality of life 
after suppression of the precursor proteins.
The review in brief
Clinical question Amyloidosis is a family of rare, progressive, multisystem diseases, in which a significant delay in 
diagnosis of classification can be fatal. This review attempts to increase the awareness of and review 
the classification, clinical presentation, diagnosis, and treatment of localized and systemic amyloidosis
Type of review Narrative
Conclusions Recent improvements with immunogold electron microscopy and laser microdissection and mass 
spectrometry have improved the classification of amyloidosis. Newer anti-plasma cell, antimicrobial, 
anti-inflammatory agents, and small molecules have improved outcomes in systemic amyloidosis
Limitations This is a brief overview of several distinct diseases, unified by formation of amyloid fibrils. The patient 
characteristics, natural history, and treatment of each subtype can differ significantly, allowing for only 
an overview, rather than an in depth review
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